PADN-PH-LHD
2026
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of Single-use Ring-shaped Pulmonary Artery Radiofrequency Ablation Catheter and Pulmonary Artery RF Ablation Generator for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
In 264 patients with pulmonary hypertension due to heart failure, pulmonary artery denervation reduced clinical worsening compared with medical therapy alone.
Result
Efficacy: Clinical worsening: first occurrence of any of: intravenous inotropes, diuretics or vasodilators for worsening heart failure; rehospitalisation for heart failure; 6-minute walk distance decrease >10 % or >30 m from baseline; referral for heart or heart–lung transplantation; all-cause death, assessed when the last enrolled patient has ≥6 months of follow-upHR 0.49 (95% CI 0.30-0.82) · P = 0.006
Below 1 favours pulmonary artery denervation, above 1 favours medical therapy alone.
- Absolute difference
- 25.8 points
- NNT
- 4
Absolute difference and NNT are derived from the event rates.
Also reported: Kaplan-Meier estimated over a median follow-up of 338 days. Access-site haematoma in 2 of 134 denervation patients and 1 of 130 controls, with no other procedural complications; adverse events during follow-up were similar in both groups.
- Subtopic
- Pulmonary artery denervation
- Design
- phase 3 device trial, prospective, multicentre (up to 39 centres in China), randomised 1:1, open-label with blinded outcome assessment; pulmonary artery denervation plus guideline-directed medical therapy vs guideline-directed medical therapy alone (no sham procedure); primary analysis when the last enrolled patient reaches 6 months; follow-up to 3 years; control patients may cross over to PADN at 12 months
- Relevance
- Important: one of several pillars.
- Source
- Zhang H, Wang L, Liang X, et al. N Engl J Med. 2026; published online 30 August.doi 10.1056/nejmoa2609056
Discussion & critique
A halving of clinical worsening from a single catheter procedure, in a group with no treatment of its own: pulmonary hypertension from left heart disease is where the pulmonary vasodilators have repeatedly failed, so a positive device trial here is genuinely new. Three things bound it. The median follow-up is 338 days while the estimate quoted is at two years, so the curve's second half rests on few patients; the control arm received a procedure-free comparison, which in a composite carrying outpatient worsening and a walk-distance decline is the weakest part of the design; and the trial is Chinese, single-country, sponsored by the device maker. The effect is large enough to matter and the confirmation should be blinded.